Post-Conference Day

Thursday, September 1, 2022

9.00 - 12.00 Workshop C

9.00 - 12.00 Workshop D

Navigating & Hijacking the Dynamic, Mechanical Lung Extracellular Matrix in IPF

Forecasting the Repercussions of the COVID-19 Pandemic on Pulmonary Fibrosis

Join this workshop to delve into the lung extracellular matrix, and investigate and consider the impact of the dynamic and mechanical forces in the lung environment, to better create experimental systems that effectively mimic human conditions.

Leave this session with the actionable knowledge to create experimental systems that can be efficiently and effectively translated to human studies, and understand emerging role of tissue stiffness and targets downstream, moving away from fibroblasts as targets.

Discussion highlights include:

  • How does the ECM change overtime?
  • How does the local environment look differently across diseased tissue?
  • How to modify the scar environment and ECM environment to be more like healthy tissue?
  • How does IPF disrupt the mechanical homeostasis of the lung environment?
  • How do certain drugs prevent changes and how to activate it with mechanical forces or biological stimuli?
  • How to source disease cells or relevant healthy cells that can be injured for stretch and tension platforms?

Patricia Sime, Professor, Virginia Commonwealth University
Cedric Hubeau
, Director, Fibrosis, AbbVie

Jeffrey Horowitz, Professor, Ohio State University

Join this workshop explore the effects of COVID-19 on both the pulmonary fibrosis future and on patients already diagnosed with IPF.

Leave this session invigorated with a debate on navigating pulmonary fibrosis in a post-COVID-19 World and what can we expect the effects of the pandemic to be in the next 10 years.

Discussion highlights include:

  • Exploring where post-COVID fibrosis fits in terms of ILD characterization
  • Clarifying the transition towards fibrotic changes and resolution of fibrosis within COVID patients
  • Verifying the new clinical work into COVID-19 patients and assessing whether there is indication of lung fibrosis
  • Accentuating the current understanding of data, examining how COVID-19 either causes or worsens fibrosis in those with IPF as an underlying health condition
  • Illuminating who survived COVID-19 with pre-existing IPF and how will that impact lung function going forward
  • Linking metabolic dysregulation and why this could lead to lung fibrosis

Marilyn Glassberg, Professor, University of Arizona
Carolyn Baglole,
Associate Professor, McGill University

13.00 - 16.00 Workshop E

13.00 - 16.00 Workshop F

Opening Up a World of Possibility: Unlocking the Single- Cell RNA-Sequencing as a Precision Approach for IPF Novel Target Identification

Switching Focus: Pursuing Inhalation Drug Delivery Methods for the Treatment of IPF

Join this workshop to harness the latest insights of single-cell RNA-sequencing and delve into the world of possibility of novel targets for IPF research.

With the explosion of a new population of cells join this workshop to learn, collaborate, and discover the realm of possibility to target the drivers of IPF with leading IPF experts.

Discussion highlights include:

  • Harnessing and interpreting single cell sequencing technology for novel
    target identification
  • Understanding the basic science of single cell sequencing technology for IPF
  • Addressing identifying new targets and discussing the cell types that are driving the fibrotic process
  • Cultivating spatial evaluation of cell-to-cell interactions to see how cells may affect each other
  • Using the available datasets: leveraging single cell sequencing to evaluate which novel target to pursue for IPF drug development
  • Effectively and efficiently using the available data sets to convincingly demonstrate novel targets
  • Reimagining biomarkers as a result of single-cell RNA sequencing
  • Comparing IPF single-nuclear RNA-sequencing with single-cell RNA sequencing

Taylor Adams, Research Assistant, Yale University
Workshop Leader To Be Confirmed, Pliant Therapeutics

Inhalation drug delivery methods are being brought into the spotlight biopharma evaluates the pros and cons of inhalation as the most effective and efficient drug delivery method, going straight to the lung.

Join this workshop to equip yourself and your team with the knowledge you need to pivot from one formulation to another, harnessing lessons learned by peers and turbocharging the IPF field forward.

Discussion highlights include:

  • Introducing benefits and risk of inhaled therapies in treating IPF
  • Discussing the importance of PK/PD relationship and methods to characterize a drug’s ability to take advantage of inhaled delivery
  • Exploring formulation and product considerations to maximise patient benefit and regulatory requirements
  • Leveraging past experiences to maximize inhaled product development

Mark Surber, Founder & Chief Scientific Officer, Avalyn Pharma
Eric Meltzer,
VP of Clinical Development Respiratory, Pieris Pharmaceuticals
Bertil Lindmark,
Chief Medical Officer, Galecto